|

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

RECRUITINGPhase 1Sponsored by Genentech, Inc.
Actively Recruiting
PhasePhase 1
SponsorGenentech, Inc.
Started2026-06-23
Est. completion2030-07-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07558915

Summary

This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \[PIs\], immunomodulators \[IMiDs\], and anti-cluster of differentiation 38 \[anti-CD38\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Life expectancy of at least 12 weeks.
* Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria.
* Measurable disease.

Exclusion Criteria:

* Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to first dose of study treatment.
* Autologous stem cell transplant (SCT) with insufficient time prior to first dose of study treatment.
* Prior allogeneic SCT.
* Prior solid organ transplantation.

Conditions2

CancerRelapsed/ Refractory Multiple Myeloma

Interventions1

RO7851624

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.